Abstract
Objective
It has been reported that levels of soluble CD30 in serum and joint fluid are significantly elevated in patients with rheumatoid arthritis (RA). This study aimed to investigate whether CD30 could be a therapeutic target for RA.
Methods
The expression and localization of CD30 were examined by immunohistochemical and double immunofluorescence staining on synovial tissue samples obtained from patients with RA or osteoarthritis (OA) during surgery. Changes in CD30 expression of fibroblast-like synoviocytes (FLS) from RA patients with or without TNFα and IL-1β stimulation were examined by the polymerase chain reaction (PCR) and flow cytometry. Collagen antibody-induced arthritis (CAIA) was created in DBA/1 mice, and the therapeutic effect of brentuximab vedotin (BV) was examined by clinical score, histological findings and measurement of serum levels of SAA, IL-6, and TNFα.
Results
CD30 expression was significantly higher in samples from patients with RA than from those with OA. Double immunofluorescence showed a low rate of co-localization of CD30 with CD20 or CD90, but a high rate of co-localization of CD30 and CD138. CD30 mRNA expression was upregulated 11.7-fold in FLS following stimulation by inflammatory cytokines. The clinical scores of CAIA mice were significantly lower following both BV treatments, however, the histological scores of CAIA mice were significantly lower only following treatment with high dose BV (70 mg/kg).
Conclusions
CD30 was expressed on immunocompetent cells in synovial tissue from RA patients and in cytokine-stimulated FLS in vitro. High dose BV (70 mg/kg) showed significant therapeutic effects in ameliorating inflammation and joint destruction in CAIA mice, but low dose BV (30 mg/kg) was insufficient.
Similar content being viewed by others
References
Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum. 2010;62:1576–82.
Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.
Wijbrandts CA, Tak PP. Prediction of response to targeted treatment in rheumatoid arthritis. Mayo Clin Proc. 2017;92:1129–43.
Gottenberg JE, Brocq O, Perdriger A, Lassoued S, Berthelot JM, Wendling D, et al. Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA. 2016;316:1172–80.
Smith CA, Gruss HJ, Davis T, Anderson D, Farrah T, Baker E, et al. CD30 antigen, a marker for Hodgkin’s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell. 1993;73:1349–60.
Stein H, Mason DY, Gerdes J, O’Connor N, Wainscoat J, Pallesen G, et al. The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848–58.
Kim WY, Nam SJ, Kim S, Kim TM, Heo DS, Kim C-W, et al. Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities. Leuk Lymphoma. 2015;56:1778–86.
Caligaris-Cappio F, Bertero MT, Converso M, Stacchini A, Vinante F, Romagnani S, et al. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol. 1995;13:339–43.
Bengtsson A, Holm L, Back O, Fransson J, Scheynius A. Elevated serum levels of soluble CD30 in patients with atopic dermatitis (AD). Clin Exp Immunol. 1997;109:533–7.
Heshmat NM, El-Hadidi ES. Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its relationship with disease severity in pediatric age. Pediatr Allergy Immunol. 2006;17:297–303.
Pizzolo G, Vinante F, Nadali G, Krampera M, Morosato L, Chilosi M, et al. High serum level of soluble CD30 in acute primary HIV-1 infection. Clin Exp Immunol. 1997;108:251–3.
Gerli R, Muscat C, Bistoni O, Falini B, Tomassini C, Agea E, et al. High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. Clin Exp Immunol. 1995;102:547–50.
Gerli R, Pitzalis C, Bistoni O, Falini B, Costantini V, Russano A, et al. CD30+ T cells in rheumatoid synovitis: mechanisms of recruitment and functional role. J Immunol. 2000;164:4399–407.
Tinazzi E, Barbieri A, Rigo A, Patuzzo G, Beri R, Gerli R, et al. In rheumatoid arthritis soluble CD30 ligand is present at high levels and induces apoptosis of CD30+ T cells. Immunol Lett. 2014;161:236–40.
Barbieri A, Dolcino M, Tinazzi E, Rigo A, Argentino G, Patuzzo G, et al. Characterization of CD30/CD30L+ cells in peripheral blood and synovial fluid of patients with rheumatoid arthritis. J Immunol Res. 2015; 2015:729654.
Sun X, Yamada H, Shibata K, Muta H, Tani K, Podack ER, et al. CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice. J Immunol. 2010;185:2222–30.
Shinoda K, Sun X, Oyamada A, Yamada H, Muta H, Podack ER, et al. CD30 ligand is a new therapeutic target for central nervous system autoimmunity. J Autoimmun. 2015;57:14–23.
Somada S, Muta H, Nakamura K, Sun X, Honda K, Ihara E, et al. CD30 ligand/CD30 interaction is involved in pathogenesis of inflammatory bowel disease. Dig Dis Sci. 2012;57:2031–7.
Artinger K, Kirsch AH, Mooslechner AA, Cooper DJ, Aringer I, Schuller M, et al. Blockade of tumor necrosis factor superfamily members CD30 and OX40 abrogates disease activity in murine immune-mediated glomerulonephritis. Kidney Int. 2021;100(2):336–48.
Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res. 2011;17:6428–36.
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812–21.
Sekiguchi Y, Iizuka H, Takizawa H, Sugimoto K, Sakajiri S, Inano T, et al. A case of methotrexate-associated Hodgkin lymphoma in a patient with rheumatoid arthritis successfully treated with brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine (BV+ AVD). Intern Med. 2020;59(17):2165-71.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis & Rheum. 1986;29:1039–49.
Nishida K, Komiyama T, Miyazawa S, Shen ZN, Furumatsu T, Doi H, et al. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum. 2004;50:3365–76.
Hutamekalin P, Saito T, Yamaki K, Mizutani N, Brand DD, Waritani T, et al. Collagen antibody-induced arthritis in mice: development of a new arthritogenic 5-clone cocktail of monoclonal anti-type II collagen antibodies. J Immunol Methods. 2009;343:49–55.
Terato K, Hasty KA, Reife RA, Cremer MA, Kang AH, Stuart JM. Induction of arthritis with monoclonal antibodies to collagen. J Immunol. 1992;148:2103–8.
Sancho D, Gómez M, Viedma F, Esplugues E, Gordón-Alonso M, García-López MA, et al. CD69 downregulates autoimmune reactivity through active transforming growth factor-β production in collagen-induced arthritis. J Clin Investig. 2003;112:872–82.
Gerli R, Lunardi C, Bocci EB, Bobbio-Pallavicini F, Schillaci G, Caporali R, et al. Anti-tumor necrosis factor-alpha response in rheumatoid arthritis is associated with an increase in serum soluble CD30. J Rheumatol. 2008;35:14–9.
Ulusoy H, Kamanli A, Ilhan N, Kuru O, Arslan S, Alkan G, et al. Serum levels of soluble CD26 and CD30 and their clinical significance in patients with rheumatoid arthritis. Rheumatol Int. 2012;32:3857–62.
Gerli R, Lunardi C, Vinante F, Bistoni O, Pizzolo G, Pitzalis C. Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol. 2001;22:72–7.
Sun X, Yamada H, Shibata K, Muta H, Tani K, Podack ER, et al. CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses. J Immunol. 2010;185:7671–80.
Durkop H, Foss HD, Eitelbach F, Anagnostopoulos I, Latza U, Pileri S, et al. Expression of the CD30 antigen in non-lymphoid tissues and cells. J Pathol. 2000;190:613–8.
Andreesen R, Brugger W, Löhr G, Bross K. Human macrophages can express the Hodgkin’s cell-associated antigen Ki-1 (CD30). Am J Pathol. 1989;134:187.
Agrawal B, Reddish M, Longenecker BM. CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors. J Immunol. 1996;157:3229–34.
Berro AI, Perry GA, Agrawal DK. Increased expression and activation of CD30 induce apoptosis in human blood eosinophils. J Immunol. 2004;173:2174–83.
Shanebeck KD, Maliszewski CR, Kennedy MK, Picha KS, Smith CA, Goodwin RG, et al. Regulation of murine B cell growth and differentiation by CD30 ligand. Eur J Immunol. 1995;25:2147–53.
Kim H-J, Krenn V, Steinhauser G, Berek C. Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. J Immunol. 1999;162:3053–62.
Moller P, Matthaei-Maurer DU, Moldenhauer G. CD30(Ki-1) antigen expression in a subset of gastric mucosal plasma cells and in a primary gastric plasmacytoma. Am J Clin Pathol. 1989;91:18–23.
Nygaard G, Firestein GS. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat Rev Rheumatol. 2020;16:316–33.
Lee DM, Kiener HP, Agarwal SK, Noss EH, Watts GF, Chisaka O, et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science. 2007;315:1006–10.
Eichenauer DA, Simhadri VL, von Strandmann EP, Ludwig A, Matthews V, Reiners KS, et al. ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro. Can Res. 2007;67:332–8.
Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458–65.
Bowen MA, Lee RK, Miragliotta G, Nam SY, Podack ER. Structure and expression of murine CD30 and its role in cytokine production. J Immunol. 1996;156:442–9.
Nandakumar KS, Holmdahl R. Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis. Arthritis Res Ther. 2007;8:1–11.
Acknowledgements
Approval was obtained from the ethics committee of Okayama University Graduate School of Medicine (Approval No. 1712-026). The procedures used in this study adhered to the tenets of the Declaration of Helsinki. All patients gave informed consent to take part in the study. All the animal experiments were approved by the Animal Care and Use Committee, Okayama University (Approval No. OKU-2018446) and carried out in accordance with relevant guidelines and regulations.
Funding
This research was supported by JSPS KAKENHI under Grant Number JP20K09433. Partial financial support was received from Eisai Co., Ltd. (Grant number: HHCS20180824007), AbbVie GK (Grant number: 793), Mitsubishi Tanabe Pharma Corp. (Grant number: MTPS20190610039), and Chugai Pharmaceutical Co., Ltd (Grant number: AC-1-20200621233833-796001).
Author information
Authors and Affiliations
Corresponding author
Additional information
Responsible Editor: John Di Battista.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Matsuhashi, M., Nishida, K., Sakamoto, M. et al. CD30-targeted therapy induces apoptosis of inflammatory cytokine-stimulated synovial fibroblasts and ameliorates collagen antibody-induced arthritis in mice. Inflamm. Res. 71, 215–226 (2022). https://doi.org/10.1007/s00011-021-01537-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00011-021-01537-z